---
title: "Astria Therapeutics (ATXS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATXS.US.md"
symbol: "ATXS.US"
name: "Astria Therapeutics"
industry: "Biotechnology"
datetime: "2026-05-21T07:32:25.006Z"
locales:
  - [en](https://longbridge.com/en/quote/ATXS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATXS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATXS.US.md)
---

# Astria Therapeutics (ATXS.US)

## Company Overview

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: D (0.61)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -23.98% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 706000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -64.56% | E |
| Profit Margin | -17567.99% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -23.98% | D |
| Total Assets YoY | -24.82% | E |
| Net Assets YoY | -31.73% | E |
| Cash Flow Margin | 96.54% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.00 | E |
| Gearing Ratio | 14.20% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Astria Therapeutics",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.98%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "706000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-64.56%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-17567.99%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.98%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-24.82%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-31.73%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "96.54%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.20%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.79 | 401/386 | - | - | - |
| PB | 5.21 | 303/386 | 5.21 | 5.15 | 1.94 |
| PS (TTM) | 1017.18 | 319/386 | 1028.50 | 1017.18 | 1017.18 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-12T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 13% |
| Hold | 7 | 88% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.58 |
| Highest Target | 49.00 |
| Lowest Target | 13.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATXS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATXS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATXS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATXS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**